Navamedic Q1 2024: Successful product launch and steady operational progress
Oslo, 30 April 2024 – In the first quarter 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, had revenues of NOK 121 million and an adjusted EBITDA of NOK 8.5 million. Revenues were at the same level as last year. Adjusted EBITDA was in line with the previous quarter, but below last year. The company had steady operational progress and rolling 12 months revenues increased 15 percent year-over-year. The first three months of 2024 were marked by normal fluctuation in revenue between quarters, due to